Glenzocimab in other indications

For Acute Respiratory Distress Syndrome (ARDS)

In response to the global COVID-19 pandemic, Acticor Biotech proposed using glenzocimab to treat acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients, in the context of a phase 2 clinical study (GARDEN NCT04659109).

The scientific rationale was to limit the contribution of platelets to uncontrolled pulmonary inflammation and prevent the secondary effect of a pro-thrombotic environment without inducing bleeding.

In February 2022, Acticor Biotech announced results of this exploratory study conducted in France and in Brazil between December 2020 and June 2021, in a total of 62 randomized patients (30 to glenzocimab and 32 to placebo):
- The safety data analysis confirmed the good tolerability of glenzocimab administered at a daily dose of 1000 mg for three consecutive days, despite concomitant treatment with heparins in all patients.
- No difference was shown for the primary efficacy endpoint of progression from moderate to severe respiratory distress between glenzocimab and the placebo, both administered in conjunction with the standard of care.

GARDEN results were presented by Pr Julien Pottecher, Coordinating Investigator of GARDEN Study, at the European Respiratory Society Congress 20221 (link to press release).